Hepatitis C
Updated: 03/22/2006

References

Abakumova OI, Kutsenko NG, et al. [Stimulation of regenerative processes and correction of the functional activity of the liver in its partial resection and toxic lesions]. Vestn Ross Akad Med Nauk. 1996;(5):36–41.

al-Faleh FZ, Ramia S, et al. Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: A community-based study. Ann Trop Med Parasitol. 1995 Aug;89(4):431–7.

Amarapurkar D. Natural history of hepatitis C virus infection. J Gastroenterol Hepatol. 2000 May;15 Suppl:E105–10.

Bailon P, Palleroni A, et al. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001 Mar;12(2):195–202.

Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: Three case histories. Med Klin (Munich). 1999 Oct 15;94 Suppl 3:84–9.

Bottiglieri T, Hyland K, et al. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs. 1994 Aug;48(2):137–52.

Boucher E, Bourienne A, et al. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut. 1997 Jul;41(1):115–20.

Centers for Disease Control and Prevention (CDC). Available at http://www.cdc.gov/ncidod/dhqp/pdf/bbp/Exp_to_Blood.pdf

Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant. 2001 Sep;1(3):197–203.

Christie JM, Chapman RW. Combination therapy for chronic hepatitis C: Interferon and ribavirin. Hosp Med. 1999 May;60(5):357–61.

Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997 Sep;26(3 Suppl 1):34S–8S.

Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1):66S–70S.

Esteban JI, Gonzalez A, et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med. 1990 Oct 18;323(16):1107–12.

Fargion S, Fracanzani AL, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol. 1997 May;9(5):497–503.

Fong TL, Han SH, et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol. 1998 Mar;28(3):369–74.

Fried MW, Shiffman ML, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975–82.

Gossrau R, Franz H. Histochemical response of mice to mistletoe lectin I (ML I). Histochemistry. 1990;94(5):531–7.

Guyton KZ, Kensler TW. Prevention of liver cancer. Curr Oncol Rep. 2002 Nov;4(6):464–70.

Hallberg L, Brune M, et al. Calcium: Effect of different amounts on nonheme- and heme-iron absorption in humans. Am J Clin Nutr. 1991 Jan;53(1):112–9.

Harvey J, Colin-Jones DG. Mistletoe hepatitis. Br Med J (Clin Res Ed). 1981 Jan 17;282(6259):186–7.

Hernandez ME, Bruguera M, et al. Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel. J Hepatol. 1992 Sep;16(1-2):56–8.

Holoman J, Glasa J, et al. [Positive effects of essential phospholipids and improvement of life style in patients with toxic liver injury]. Bratisl Lek Listy. 1998 Feb;99(2):75–81.

Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology. 1997 Sep;26(3 Suppl 1):15S–20S.

Ikeda M, Sugiyama K, et al. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun. 1998 Apr 17;245(2):549–53.

Ikeda M, Nozaki A, et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res. 2000 Jan;66(1):51–63.

Ishii K, Takamura N, et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res. 2003 Mar;25(3):226–33.

Iwasaki M, Kanda D, et al. Absence of specific symptoms in chronic hepatitis C. J Gastroenterol. 2002;37(9):709–16.

Jain SK, Pemberton PW, et al. Oxidative stress in chronic hepatitis C: Not just a feature of late stage disease. J Hepatol. 2002 Jun;36(6):805–11.

Jankovic S. [Viral hepatitis C]. Med Pregl. 1999 Nov;52(11-12):459–63.

Ko WS, Guo CH, et al. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. World J Gastroenterol. 2005 Aug 14;11(30):4697–702.

Kolho E, Naukkarinen R, et al. Transmission of hepatitis C virus to sexual partners of seropositive patients with bleeding disorders: A rare event. Scand J Infect Dis. 1991;23(6):667–70.

Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology. 2002;62 Suppl 1:94–100.

Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1):41–52.

Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep. 2004 Feb;6(1):60–5.

Martin-Vivaldi R, Nogueras F, et al. Response of chronic hepatitis C to interferon-alpha treatment and relationship with iron metabolism. Rev Esp Enferm Dig. 1997 Jul;89(7):523–30.

Mayer KE, Myers RP, et al. Silymarin treatment of viral hepatitis: A systematic review. J Viral Hepat. 2005 Nov;12(6):559–67.

McHutchinson JG, Gordon SC, et al. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis. N Engl J Med. 1998;339(21):1485–92.

Melhem A, Stern M, et al. Treatment of chronic hepatitis C virus infection via antioxidants: Results of a phase I clinical trial. J Clin Gastroenterol. 2005 Sep;39(8):737–42.

Mitsui T, Iwano K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology. 1992 Nov;16(5):1109–14.

Moriya K, Nakagawa K, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001 Jun 1;61(11):4365–70.

Murakami Y, Nagai A, et al. Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin. Nutrition. 2006 Feb;22(2):114–22.

Niederau C, Strohmeyer G, et al. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: A multi-center, randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1998 May-Jun;45(21):797–804.

Oneta CM, Mak KM, et al. Dilinoleoylphosphatidylcholine selectively modulates lipopolysaccharide-induced Kupffer cell activation. J Lab Clin Med. 1999 Nov;134(5):466–70.

Puoti C, Pannullo A, et al. Ursodeoxycholic acid and chronic hepatitis C infection. Lancet. 1993 May 29;341(8857):1413–4.

Reddy KR, Wright TL, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001 Feb;33(2):433–8.

Reizis AR, Malinovskaia VV, et al. [Effectiveness of using recombinant interferon alfa2 (reaferon) combined with antioxidants in children with acute hepatitis B]. Pediatriia. 1992;(1):60–4.

Sachithanandan S, Fielding JF. Low rate of hepatitis C transmission from women infected with contaminated anti-D immunoglobulin to their family contacts. Ital J Gastroenterol Hepatol. 1997 Feb;29(1):47–50.

Sharieff KA, Duncan D, et al. Advances in treatment of chronic hepatitis C: ‘Pegylated’ interferons. Cleve Clin J Med. 2002 Feb;69(2):155–9.

Sonnenbichler J, Zetl I. [Mechanism of action of silibinin. V. Effect of silibinin on the synthesis of ribosomal RNA, mRNA and tRNA in rat liver in vivo]. Hoppe Seylers Z Physiol Chem. 1984 May;365(5):555–66.

Sonnenbichler J, Goldberg M, et al. Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: Non-response in hepatoma and other malign cell lines. Biochem Pharmacol. 1986a Feb 1;35(3):538–41.

Sonnenbichler J, Zetl I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog Clin Biol Res. 1986b;213:319–31.

Swain RA, St Clair L. The role of folic acid in deficiency states and prevention of disease. J Fam Pract. 1997 Feb;44(2):138–44.

Thomas DL. Hepatitis C: Epidemiologic quandaries. Clin Liver Dis. 2001 Nov;5(4):955–68.

Tsai NC, Zuckerman E, et al. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol. 1997 Oct;92(10):1831–4.

Tsubota A, Kumada H, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: A randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999 Oct;11(10):1077–83.

Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res. 1994;27(2):105–12.

Werner C, Wendel A. Hepatic uptake and antihepatotoxic properties of vitamin E and liposomes in the mouse. Chem Biol Interact. 1990;75(1):83–92.

Yi M, Kaneko S, et al. Hepatitis C virus envelope proteins bind lactoferrin. J Virol. 1997 Aug;71(8):5997–6002.